Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years

PET Clin. 2024 Apr 20:S1556-8598(24)00019-1. doi: 10.1016/j.cpet.2024.03.004. Online ahead of print.ABSTRACTEach tumor has its own distinctive molecular identity. Treatment, therefore, should be tailored to this unique cancer phenotype. Theragnostics uses the same compound for targeted imaging and treatment, radiolabeled to an appropriate radionuclide, respectively. Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer, and radiolabeled GRPR antagonists have shown high diagnostic performance at staging and biochemical recurrence. Several GRPR-targeting theragnostic compounds have been developed preclinically. Their translation into clinics is underway with 4 clinical trials recruiting participants with GRPR-expressing tumors.PMID:38644111 | DOI:10.1016/j.cpet.2024.03.004
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research